Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Catalyst Pharmaceuticals Inc shares valued at $609,000 were sold by Elsbernd Brian on Sep 08 ’25. At $20.30 per share, Elsbernd Brian sold 30,000 shares. The insider’s holdings dropped to 271,039 shares worth approximately $5.34 million following the completion of this transaction.
Also, Elsbernd Brian purchased 30,000 shares, netting a total of over 609,035 in proceeds.
Before that, Elsbernd Brian had sold 30,000 shares from its account. In a trade valued at $585,600, the Chief Compliance/Legal Officer traded Catalyst Pharmaceuticals Inc shares for $19.52 each. Upon closing the transaction, the insider’s holdings decreased to 30,000 shares, worth approximately $3.71 million.
As published in their initiating research note from Robert W. Baird on February 04, 2025, Catalyst Pharmaceuticals Inc [CPRX] has been an Outperform and the price target has been revised to $28. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid November. As of March 14, 2024, Citigroup has initiated its “Buy” rating for CPRX. Earlier on March 07, 2024, BofA Securities initiated its rating. Their recommendation was “a Buy” for CPRX stock.
Analyzing CPRX Stock Performance
On last trading session, Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] plunged -0.40% to $19.7. The stock’s lowest price that day was $19.5, but it reached a high of $19.98 in the same session. During the last five days, there has been a drop of approximately -1.60%. Over the course of the year, Catalyst Pharmaceuticals Inc shares have dropped approximately -5.24%. Shares of the company reached a 52-week high of $26.58 on 06/09/25 and a 52-week low of $19.15 on 08/07/25.
Support And Resistance Levels for Catalyst Pharmaceuticals Inc (CPRX)
According to the 24-hour chart, there is a support level at 19.47, which, if violated, would cause prices to drop to 19.25. In the upper region, resistance lies at 19.95. The next price resistance is at 20.21. RSI (Relative Strength Index) is 43.76 on the 14-day chart, showing neutral technical sentiment.
Is Catalyst Pharmaceuticals Inc subject to short interest?
Stocks of Catalyst Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-29 dropping by -1.3 million shares to 7.93 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 9.23 million shares. A decline of -16.37% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.56 of the overall float, the days-to-cover ratio (short ratio) decline to 5.56.
Which companies own the most shares of Catalyst Pharmaceuticals Inc (CPRX)?
In terms of Catalyst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 1.11% from the previous closing price of $19.78. Analysts anticipate Catalyst Pharmaceuticals Inc stock to reach 35 by 2025, with the lowest price target being 15.5. In spite of this, 3 analysts ranked Catalyst Pharmaceuticals Inc stock as Buy at the end of 2025. On December 21, 2023, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $30.
